Fennec Pharmaceuticals Statistics
Fennec Pharmaceuticals (RV41) Stock Statistics & Valuation Metrics
Total Valuation
Fennec Pharmaceuticals has a market cap or net worth of EUR 332.18M. The enterprise value is EUR 350.37M.
- Market Cap
- EUR 332.18M
- Enterprise Value
- EUR 350.37M
Share Statistics
Fennec Pharmaceuticals has 35,067,158 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 35,067,158
- Owned by Insiders
- 10.07%
- Owned by Institutions
- 11.55%
Financial Efficiency
Fennec Pharmaceuticals’s return on equity (ROE) is -0.28 and return on invested capital (ROIC) is -10.65%.
- Return on Equity (ROE)
- -0.28
- Return on Assets (ROA)
- -0.14
- Return on Invested Capital (ROIC)
- -10.65%
- Return on Capital Employed (ROCE)
- -0.11
- Revenue Per Employee
- 1.28M
- Profits Per Employee
- -278.31K
- Employee Count
- 35
- Asset Turnover
- 0.64
- Inventory Turnover
- 2.41
Valuation Ratios
The current PE Ratio of Fennec Pharmaceuticals is -81.38. Fennec Pharmaceuticals’s PEG ratio is -1.45.
- PE Ratio
- -81.38
- PS Ratio
- 6.26
- PB Ratio
- 8.61
- Price to FCF
- -181.87
- Price to Operating Cash Flow
- -179.16
- PEG Ratio
- -1.45
Income Statement
In the last 12 months, Fennec Pharmaceuticals had revenue of 44.64M and earned -9.74M in profits. Earnings per share was -0.36.
- Revenue
- 44.64M
- Gross Profit
- 40.88M
- Operating Income
- -6.35M
- Pretax Income
- -9.63M
- Net Income
- -9.74M
- EBITDA
- -7.45M
- Earnings Per Share (EPS)
- -0.36
Cash Flow
In the last 12 months, operating cash flow was -2.04M and capital expenditures 0, giving a free cash flow of -2.04M billion.
- Operating Cash Flow
- -2.04M
- Free Cash Flow
- -2.04M
- Free Cash Flow per Share
- -0.06
Dividends & Yields
Fennec Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -0.56%
- Earnings Yield
- -0.91%
Stock Price Statistics
- Beta
- 0.86
- 52-Week Price Change
- 44.96%
- 50-Day Moving Average
- 9.34
- 200-Day Moving Average
- 7.93
- Relative Strength Index (RSI)
- 46.36
- Average Volume (3m)
- 45
Important Dates
Fennec Pharmaceuticals upcoming earnings date is Nov 12, 2026, Before Open (Not Confirmed).
- Last Earnings Date
- Aug 11, 2026
- Next Earnings Date
- Nov 12, 2026
- Ex-Dividend Date
- ―
Financial Position
Fennec Pharmaceuticals as a current ratio of 6.34, with Debt / Equity ratio of 0.00%
- Current Ratio
- 6.34
- Quick Ratio
- 6.19
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 4.93
- Interest Coverage Ratio
- -3.05
Taxes
In the past 12 months, Fennec Pharmaceuticals has paid 106.00K in taxes.
- Income Tax
- 106.00K
- Effective Tax Rate
- -0.01
Enterprise Valuation
Fennec Pharmaceuticals EV to EBITDA ratio is -135.04, with an EV/FCF ratio of -157.35.
- EV to Sales
- 5.42
- EV to EBITDA
- -135.04
- EV to Free Cash Flow
- -157.35
- EV to Operating Cash Flow
- -157.35
Balance Sheet
Fennec Pharmaceuticals has EUR 41.25M in cash and marketable securities with EUR 0.00 in debt, giving a net cash position of EUR 41.25M billion.
- Cash & Marketable Securities
- EUR 41.25M
- Total Debt
- EUR 0.00
- Net Cash
- EUR 41.25M
- Net Cash Per Share
- EUR 1.18
- Tangible Book Value Per Share
- EUR 1.23
Margins
Gross margin is 93.73%, with operating margin of -1.96%, and net profit margin of -5.49%.
- Gross Margin
- 93.73%
- Operating Margin
- -1.96%
- Pretax Margin
- -5.24%
- Net Profit Margin
- -5.49%
- EBITDA Margin
- -4.01%
- EBIT Margin
- -4.19%
Analyst Forecast
The average price target for Fennec Pharmaceuticals is EUR 15.78, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- EUR 15.78
- Price Target Upside
- 68.80% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 5
- Revenue Growth Forecast
- 65.92%
- EPS Growth Forecast
- 72.28%
Scores
- Smart Score
- 6
- AI Score
- ―
